Insulet (PODD) Competitors $301.14 -0.49 (-0.16%) Closing price 01:23 PM EasternExtended Trading$301.14 0.00 (0.00%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PODD vs. BDX, EW, IDXX, RMD, DXCM, STE, BAX, HOLX, MASI, and GMEDShould you be buying Insulet stock or one of its competitors? The main competitors of Insulet include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), STERIS (STE), Baxter International (BAX), Hologic (HOLX), Masimo (MASI), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry. Insulet vs. Its Competitors Becton, Dickinson and Company Edwards Lifesciences IDEXX Laboratories ResMed DexCom STERIS Baxter International Hologic Masimo Globus Medical Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability. Which has preferable valuation and earnings, BDX or PODD? Becton, Dickinson and Company has higher revenue and earnings than Insulet. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBecton, Dickinson and Company$20.18B2.50$1.71B$5.2433.62Insulet$2.20B9.64$418.30M$5.5654.16 Do insiders & institutionals believe in BDX or PODD? 87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, BDX or PODD? Becton, Dickinson and Company has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Insulet has a beta of 1.35, meaning that its share price is 35% more volatile than the S&P 500. Does the media favor BDX or PODD? In the previous week, Becton, Dickinson and Company had 12 more articles in the media than Insulet. MarketBeat recorded 30 mentions for Becton, Dickinson and Company and 18 mentions for Insulet. Becton, Dickinson and Company's average media sentiment score of 1.15 beat Insulet's score of 0.96 indicating that Becton, Dickinson and Company is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Becton, Dickinson and Company 23 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 10 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Is BDX or PODD more profitable? Insulet has a net margin of 18.29% compared to Becton, Dickinson and Company's net margin of 7.28%. Insulet's return on equity of 22.25% beat Becton, Dickinson and Company's return on equity.Company Net Margins Return on Equity Return on Assets Becton, Dickinson and Company7.28% 15.99% 7.36% Insulet 18.29%22.25%8.29% Do analysts prefer BDX or PODD? Becton, Dickinson and Company presently has a consensus price target of $219.22, suggesting a potential upside of 24.44%. Insulet has a consensus price target of $321.00, suggesting a potential upside of 6.60%. Given Becton, Dickinson and Company's higher probable upside, research analysts plainly believe Becton, Dickinson and Company is more favorable than Insulet.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Becton, Dickinson and Company 0 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.36Insulet 0 Sell rating(s) 3 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryInsulet beats Becton, Dickinson and Company on 10 of the 16 factors compared between the two stocks. Get Insulet News Delivered to You Automatically Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PODD vs. The Competition Export to ExcelMetricInsuletMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.19B$10.32B$5.49B$9.01BDividend YieldN/A2.09%5.39%4.09%P/E Ratio54.1616.7427.4320.06Price / Sales9.6429.50398.25108.31Price / Cash67.6222.7836.1356.90Price / Book17.443.668.085.67Net Income$418.30M$235.40M$3.16B$248.47M7 Day Performance-2.81%1.89%2.12%2.90%1 Month Performance-6.84%3.83%4.43%5.75%1 Year Performance53.08%-10.20%35.62%21.36% Insulet Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PODDInsulet4.2166 of 5 stars$301.14-0.2%$321.00+6.6%+53.0%$21.19B$2.20B54.163,900BDXBecton, Dickinson and Company4.807 of 5 stars$169.72+0.8%$219.22+29.2%-22.8%$48.64B$20.18B32.3974,000Positive NewsEWEdwards Lifesciences4.3612 of 5 stars$75.33+2.0%$80.20+6.5%-15.6%$44.19B$5.44B10.7615,800Positive NewsIDXXIDEXX Laboratories3.7642 of 5 stars$524.65+0.1%$546.00+4.1%+13.7%$42.19B$3.90B48.4911,000Positive NewsAnalyst ForecastRMDResMed4.6352 of 5 stars$254.25+0.2%$259.33+2.0%+35.2%$37.28B$4.69B28.549,980News CoveragePositive NewsInsider TradeDXCMDexCom4.897 of 5 stars$79.84-0.2%$98.50+23.4%-25.7%$31.31B$4.03B59.5810,300Positive NewsInsider TradeSTESTERIS4.9349 of 5 stars$236.95+0.5%$263.83+11.3%+9.0%$23.31B$5.46B38.2217,787Positive NewsBAXBaxter International4.3106 of 5 stars$30.01+0.1%$37.25+24.1%-5.3%$15.40B$10.64B-27.2838,000Positive NewsHOLXHologic4.8547 of 5 stars$64.43-0.1%$77.42+20.2%-11.2%$14.36B$4.03B27.197,063Positive NewsMASIMasimo4.2195 of 5 stars$168.12+1.8%$191.60+14.0%+51.1%$9.12B$2.09B-18.335,600GMEDGlobus Medical4.9464 of 5 stars$57.82-0.1%$94.00+62.6%-11.1%$7.83B$2.52B43.155,300Analyst Revision Related Companies and Tools Related Companies Becton, Dickinson and Company Alternatives Edwards Lifesciences Alternatives IDEXX Laboratories Alternatives ResMed Alternatives DexCom Alternatives STERIS Alternatives Baxter International Alternatives Hologic Alternatives Masimo Alternatives Globus Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PODD) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insulet Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Insulet With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
